

RECORDATI: 2012 CORPORATE EVENTS' CALENDAR

Milan, 28th November 2011 – Pursuant to Article 2.6.2, paragraph 1, letter c) of Borsa Italiana S.p.A.'s Regulation, Recordati S.p.A. hereby communicates the calendar of corporate events for 2012.

- 9th February** Board of Directors' meeting to approve the 2011 preliminary consolidated results.
- 8th March** Board of Directors' meeting to approve the 2011 consolidated financial statements and the draft of Recordati S.p.A.'s 2011 financial statements.
- 19th April** Shareholders' General Meeting to approve the 2011 Financial Statements.
- 8th May** Board of Directors' meeting to approve the 2012 first quarter interim management statement.
- 9th May** Presentation to financial analysts.
- 26th July** Board of Directors' meeting to approve the 2012 half-yearly report.
- 25th October** Board of Directors' meeting to approve the 2012 first nine months' interim management statement.

Recordati, established in 1926, is a European pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of over 2,800, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. It has headquarters in Milan, Italy, operations in the main European countries, and a growing presence in the new markets of Central and Eastern Europe. A European field force of around 1,400 medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati's current and growing coverage of the European pharmaceutical market makes it a partner of choice for new product licenses from companies which do not have European marketing organizations. Recordati is committed to the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. Consolidated revenue for 2010 was € 728.1 million, operating income was € 154.8 million and net income was € 108.6 million.

For further information:

Recordati website: www.recordati.com

Investor Relations

Marianne Tatschke
(39)0248787393
e-mail: inver@recordati.it

Media Relations

Ketchum PR
Cristina Risciotti, (39)0262411919, (39)3481343116,
cristian.risciotti@ketchum.it
Marzia Ongaretti, (39)0262411915, marzia.ongaretti@ketchum.it

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Sede Legale
VIA M. CIVITALI, 1
20148 MILANO, ITALIA
TEL. (39) 0248787.1
FAX (39) 0240073747

CAPITALE SOCIALE € 26.140.644,50 I.V.
REG. IMP. MILANO N. 00748210150
CODICE FISCALE/P.IVA 007482210150
R.E.A. MILANO N. 401832